FENNEC PHARMACEUTICALS REPORTS FY SALES OF $44.6 MILLION

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: 6 days ago

0mins

FENC-2.37%

Should l Buy FENC?

Source: moomoo

Sales Performance: The pharmaceutical company reported sales of $44.6 million for its products.
Market Impact: This sales figure indicates a significant presence in the market, reflecting the company's growth and product demand.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy FENC?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on FENC

Wall Street analysts forecast FENC stock price to rise

4 Analyst Rating

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.910

Low

13.00

Averages

14.67

High

18.00

Current: 5.910

Low

13.00

Averages

14.67

High

18.00

B. Riley

Buy

initiated

$16

2026-02-12

Reason

B. Riley

Price Target

$16

AI Analysis

2026-02-12

initiated

Buy

Reason

B. Riley initiated coverage of Fennec with a Buy rating and $16 price target. The firm believes the Street is "materially" undervaluing the duration and potential expansion of Pedmark's commercial runway. Fennec shares trade 19% below the peer group median valuation despite projecting 55% revenue growth annually through 2027, which is among the highest growth rates in the sector, the analyst tells investors in a research note. Riley notes that Pedmark is the first and only FDA-approved therapy to reduce the risk of cisplatin-induced hearing loss, operating in a "validated therapeutic category with no approved competitors and limited pipeline threats for the foreseeable future."

Piper Sandler

David Amsellem

Overweight

initiated

$18

2026-01-09

Reason

Piper Sandler

David Amsellem

Price Target

$18

2026-01-09

initiated

Overweight

Reason

Piper Sandler analyst David Amsellem last night initiated coverage of Fennec with an Overweight rating and $18 price target. The firm says the company's Pedmark, its intravenous formulation of sodium thiosulfate, represents a "unique opportunity" in oncology supportive care as the only agent approved for the reduction in the risk of cisplatin-inducted ototoxicity. Piper believes peak U.S. sales potential north of $300M is realistic.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FENC

Unlock Now

About FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Fennec Pharmaceuticals Q4 2025 Earnings Report

6 days agoseekingalpha

Disappointing Earnings: Fennec Pharmaceuticals reported a Q4 GAAP EPS of -$0.17, missing expectations by $0.21, indicating challenges in profitability that may affect investor confidence.
Lackluster Revenue Growth: Despite a 73.8% year-over-year revenue increase to $13.78 million, the figure fell short of expectations by $0.95 million, reflecting intensified market competition and potential shortcomings in sales strategies.
Strong Cash Position: As of December 31, 2025, the company had $36.8 million in cash and cash equivalents, representing a $10.2 million increase from the previous year, demonstrating effective cash management that supports future operations and R&D.
No Debt Burden: Fennec Pharmaceuticals reported zero outstanding debt as of December 31, 2025, providing financial flexibility that may help mitigate risks in future investments and expansions.

FENNEC PHARMACEUTICALS INC Reports Q4 2025 Net Product Sales of $13.8 Million

6 days agomoomoo

Sales Performance: The pharmaceutical company reported net product sales of $13.8 million for the fourth quarter of 2025.
Financial Outlook: The sales figures indicate a positive trend in the company's financial performance within the pharmaceutical sector.

Fennec Pharmaceuticals Announces Financial Results for Q4 and Full Year 2025 Along with Business Update

6 days agomoomoo

Financial Results: The report covers the financial results for the fourth quarter and the full year of 2025 for a pharmaceutical company.
Business Update: It provides a business update, likely detailing performance metrics, strategic initiatives, and future outlook.

FENNEC PHARMACEUTICALS Reports FY Basic EPS of USD -0.35

6 days agomoomoo

Pharmaceutical Industry Overview: The pharmaceutical sector is experiencing significant changes, driven by advancements in technology and regulatory shifts.
Market Trends: There is a growing emphasis on personalized medicine and biologics, which are reshaping treatment approaches and market dynamics.
Regulatory Challenges: Companies face increasing scrutiny from regulatory bodies, impacting drug approval processes and market entry strategies.
Financial Performance: The financial outlook for pharmaceutical companies remains mixed, with some reporting strong earnings while others struggle with patent expirations and competition.